GPC
CLBT icon

Guardian Point Capital’s Cellebrite CLBT Stock Holding History

Guardian Point Capital’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150,000
Closed -$2.7M – 12
2025
Q4 		$2.7M Buy
+150,000
New +$2.69M 0.84% 12

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Guardian Point Capital's CLBT Position: Q1 2026 in Review

Guardian Point Capital sold out of Cellebrite (CLBT) in Q1 2026, closing a stake of 150,000 shares — an estimated $2.7M sold.

Guardian Point Capital first reported a position in CLBT in Q4 2025 and held it in 1 quarter. The position peaked at $2.7M in Q4 2025. 221 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

  • Guardian Point Capital reported no remaining Cellebrite position as of Q1 2026 after selling out during the quarter.
  • Guardian Point Capital sold 150,000 Cellebrite shares in Q1 2026, an estimated $2.7M.
  • Guardian Point Capital first reported a position in Cellebrite in Q4 2025 and held it in 1 quarter.
  • Guardian Point Capital's Cellebrite position peaked at $2.7M in Q4 2025.
  • 221 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on Guardian Point Capital's 13F filing for Q1 2026, filed 15 May 2026.